Prescription Required
Bryxta 400mg Injection 16ml contains Bevacizumab (400mg), a monoclonal antibody used primarily to treat various types of cancer, including colorectal cancer, lung cancer, kidney cancer, and ovarian cancer. It works by blocking the growth of blood vessels that supply tumors, thereby slowing their growth and spread.
This medicine is administered via intravenous infusion under the supervision of a healthcare professional. It is usually prescribed alongside other chemotherapy medications for enhanced effectiveness. Bryxta 400mg Injection plays a crucial role in cancer treatment by inhibiting vascular endothelial growth factor (VEGF), a protein responsible for tumor blood vessel formation.
Patients undergoing treatment with Bryxta 400mg Injection should follow their doctor’s recommendations closely to minimize side effects and enhance treatment outcomes. Proper monitoring and regular medical check-ups are essential while using this medication.
There is limited information on alcohol interactions. However, it is best to avoid alcohol to prevent possible complications.
Not recommended during pregnancy as it may cause fetal harm. Use effective contraception during and after treatment.
Avoid breastfeeding while using this medicine, as it may pass into breast milk and harm the baby.
Bryxta 400mg Injection may cause dizziness or vision changes. Avoid driving if you experience these effects.
Caution is advised in patients with kidney disease. Regular monitoring of kidney function is recommended.
Patients with liver conditions should consult their doctor before starting treatment with Bryxta Injection.
Bryxta 400mg Injection contains Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein responsible for promoting blood vessel growth essential for tumor survival and spread. By blocking VEGF, Bryxta 400mg Injection prevents the formation of new blood vessels in tumors, cuts off their blood supply, and slows or halts tumor growth. This mechanism helps reduce tumor progression and improve survival rates in cancer patients.
Cancer is a disease in which abnormal cells grow uncontrollably, leading to tumor formation. These tumors require blood supply to grow, a process known as angiogenesis. Bevacizumab (in Bryxta 400mg Injection) blocks angiogenesis, starving tumors and slowing disease progression.
Bryxta 400mg Injection (Bevacizumab 400mg) is an anti-cancer drug that slows tumor growth by blocking blood vessel formation. It is used for treating lung, colorectal, kidney, and ovarian cancers. Administered under medical supervision, it improves survival rates and enhances chemotherapy effectiveness. Patients should follow their doctor's advice, maintain a healthy lifestyle, and monitor for side effects during treatment.
Content Updated on
Wednesday, 26 Feburary, 2025Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA